Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2020 in San Francisco
January 06 2020 - 7:00AM
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP)
("Cyclacel" or the "Company"), a biopharmaceutical company
developing innovative medicines based on cancer cell biology,
announces that the Company will present at Biotech Showcase™ 2020,
at 9:30 a.m. PT on January 13, in the Yosemite A
(Ballroom level) at the Hilton San Francisco Union
Square. Spiro Rombotis, President & Chief Executive
Officer, will provide an overview of the Company and progress in
key programs.
A live webcast of the presentation will be available through the
Company's website: www.cyclacel.com. The webcast will be archived
for 90 days.
About Cyclacel Pharmaceuticals, Inc. Cyclacel
Pharmaceuticals is a clinical-stage biopharmaceutical company
developing innovative cancer medicines based on cell cycle,
transcriptional regulation and DNA damage response biology. The
transcriptional regulation program is evaluating CYC065 as a single
agent in solid tumors and in combination with venetoclax in
patients with relapsed or refractory CLL and AML/MDS. The DNA
damage response program is evaluating an oral combination regimen
of sapacitabine and venetoclax in patients with relapsed or
refractory AML/MDS. An IST is evaluating an oral combination
regimen of sapacitabine and olaparib in patients with BRCA mutant
breast cancer. The anti-mitotic program is evaluating CYC140, a
PLK1 inhibitor, in AML/MDS patients. Cyclacel's strategy is to
build a diversified biopharmaceutical business focused in
hematology and oncology based on a pipeline of novel drug
candidates. For additional information, please visit
www.cyclacel.com.
Forward-looking Statements
This news release contains certain forward-looking statements
that involve risks and uncertainties that could cause actual
results to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. Such forward-looking statements include statements
regarding, among other things, the efficacy, safety and intended
utilization of Cyclacel's product candidates, the conduct and
results of future clinical trials, plans regarding regulatory
filings, future research and clinical trials and plans regarding
partnering activities. Factors that may cause actual results to
differ materially include the risk that product candidates that
appeared promising in early research and clinical trials do not
demonstrate safety and/or efficacy in larger-scale or later
clinical trials, trials may have difficulty enrolling, Cyclacel may
not obtain approval to market its product candidates, the risks
associated with reliance on outside financing to meet capital
requirements, and the risks associated with reliance on
collaborative partners for further clinical trials, development and
commercialization of product candidates. You are urged to consider
statements that include the words "may," "will," "would," "could,"
"should," "believes," "estimates," "projects," "potential,"
"expects," "plans," "anticipates," "intends," "continues,"
"forecast," "designed," "goal," or the negative of those words or
other comparable words to be uncertain and forward-looking. For a
further list and description of the risks and uncertainties the
Company faces, please refer to our most recent Annual Report on
Form 10-K and other periodic and other filings we file with the
Securities and Exchange Commission and are available at
www.sec.gov. Such forward-looking statements are current only as of
the date they are made, and we assume no obligation to update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contacts |
Company: |
Paul McBarron,
(908) 517-7330, pmcbarron@cyclacel.com |
Investor Relations: |
Russo Partners LLC, Jan Medina, (646) 942-5632,
Jan.Medina@russopartnersllc.com |
© Copyright 2020 Cyclacel Pharmaceuticals, Inc. All Rights
Reserved. The Cyclacel logo and Cyclacel® are trademarks of
Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Historical Stock Chart
From Apr 2023 to Apr 2024